ProMIS Neurosciences Phase 1b data show zero ARIA and p-tau217 reduction
Interim Phase 1b Alzheimer’s trial data for a novel antibody platform targeting misfolded proteins report zero ARIA cases and a significant p-tau217 reduction. Top-line results are expected in Q1 2027.